Tronox Holdings PLC

This proposal asks shareholders to cast a non-binding, advisory vote to approve the compensation disclosed for the named executive officers (NEOs), including the Compensation Discussion and Analysis and compensation tables. Management positions this vote as a mechanism for shareholders to express their view on the overall philosophy and outcomes of the executive compensation program rather than any single payment. The Board and its HRCC recommend FOR because they believe pay is aligned with long‑term shareholder value through a mix of competitive base salary, annual incentives tied to company and individual performance (including ESG-linked metrics), and long‑term equity awards (time-based and performance-based RSUs tied to TSR and ROIC). The proposal is advisory and non-binding, but the Board commits to consider shareholder feedback and voting results in its ongoing evaluation of compensation practices. The proxy will be voted FOR by management proxies unless shareholders give other instructions. The company frames the program as designed to attract and retain talent, pay for performance, and align executives’ interests with shareholders, and notes corporate governance safeguards such as clawback provisions and limits on repricing. From an analytical perspective, the vote functions as a governance signal: high support validates current pay design and calibration, while low support would trigger substantive review and potential changes by the HRCC. The advisory nature means implementation risk is low, but reputational and engagement risks for management are real if dissent is significant.

This proposal is a statutory, advisory resolution to receive the Company’s U.K. audited annual report and accounts and accompanying directors’ and auditors’ reports for the 2025 fiscal year. It does not change company policy or trigger binding action; rather, it gives shareholders the opportunity to formally acknowledge receipt of the audited financial statements as required under the Companies Act. Management recommends FOR as customary, and the proxy will be voted in favor absent contrary instructions. For analysts, this vote is largely procedural but provides a venue for shareholders to raise questions about accounting, audit quality, and disclosures; significant opposition would be an early indicator of concerns about financial reporting or audit integrity. The company also makes the auditors available to answer questions at the meeting, which can be an important engagement touchpoint. Given the detailed audit committee report and auditor disclosures in the proxy, receipt is expected to pass without controversy, and the outcome should be interpreted in context with other governance votes rather than as an independent signal.

This is a binding, statutory proposal under the Companies Act to approve the U.K. Directors’ Remuneration Policy, which governs how executive and non-executive directors are paid over the policy term (typically up to three years). Management is seeking shareholder approval to formalize forward-looking remuneration arrangements, including base salary review processes, annual incentive design, long-term incentive structure, pension and benefit provisions, and caps (e.g., non-employee director annual equity cap). The Board justifies the policy as substantially consistent with the policy approved in 2023, and argues it balances competitiveness (to attract and retain talent) with alignment to shareholder outcomes through performance-linked equity and clawback provisions. A binding approval provides legal certainty for director pay and avoids the need for repeated ad hoc approvals; failure to pass would impose administrative burdens and could constrain the company’s ability to deliver expected director compensation. For governance analysts, the motion should be evaluated on pay-for-performance alignment, use of performance metrics (TSR, ROIC), cap levels, post-employment payments, and discretion retained by the HRCC. The Board recommends FOR and frames the policy as preserving governance safeguards (clawbacks, no liberal recycling, no repricing without approval). Passage indicates institutional investor comfort; defeat would create significant governance and retention implications and likely lead to an updated policy and additional shareholder engagement.

This advisory proposal requests shareholder endorsement of the Company’s disclosures about how the U.K. Directors’ Remuneration Policy was implemented during 2025, including single‑figure totals, incentive outcomes, and narrative justification. Management treats the vote as non-binding but meaningful: the HRCC will review outcomes and investor feedback to refine future pay decisions. The report provides detail on CEO and other director pay, the mix of fixed vs. variable pay, the application of performance measures (including TSR and ROIC in long‑term incentives), and governance features like clawbacks and shareholding guidelines. From an analytical standpoint, the vote gauges investor satisfaction with pay outcomes given 2025’s challenging market environment and specific forfeitures/vestings described in the CD&A. A strong FOR vote signals alignment; a weak vote would likely trigger enhanced engagement and potential compensation design changes. The proxy confirms management will vote FOR in the absence of contrary instructions. Overall, this advisory resolution is a performance and governance feedback mechanism rather than a prescriptive change in pay.

The company asks shareholders to approve the re-appointment of PwC U.K. as the statutory auditor for the UK entity, a requirement under the Companies Act when presenting audited accounts. The Audit Committee reviewed PwC’s independence, performance, and audit quality indicators and recommends re-appointment. This is a routine statutory motion with limited controversy; management will vote proxies FOR unless instructed otherwise. For analysts, the key considerations are audit fees, audit committee oversight, and any disclosed non‑audit services and pre‑approval policies; the proxy discloses fee levels and pre-approval procedures. While typically a low‑risk governance item, a contested or negative outcome would raise questions about auditor relationships or independence. The motion reinforces the Board’s and Audit Committee’s current audit arrangements and commitment to audit quality and regulatory compliance.

This ordinary resolution asks shareholders to grant the Board or its Audit Committee authority to set the remuneration of the U.K. statutory auditor, PwC U.K., as permitted under the Companies Act. The proposal is procedural and intended to delegate administrative authority to the Board/Audit Committee for efficiency while preserving audit committee oversight and pre-approval safeguards. Management recommends FOR, and proxy votes will generally be cast in favor absent instructions. From a governance perspective, analysts will look to ensure the Audit Committee retains appropriate independence and pre-approval controls over non-audit services to avoid conflicts of interest; the proxy outlines pre-approval rules and fee disclosure. Passing this resolution streamlines routine governance without changing the substantive engagement terms with the auditor.

This ordinary resolution seeks shareholder authorization under section 551 of the Companies Act to permit the Board to allot new shares or grant rights to subscribe for or convert securities into shares up to a specified nominal amount (about 20% of issued capital). The company frames this as routine and pragmatic: it replaces prior authority and is intended primarily to allow the Board to meet equity award obligations and maintain corporate financing flexibility without calling a general meeting. Management recommends FOR, arguing the authority is time-limited and consistent with UK corporate practice; the Board notes no present intention to use it except to satisfy incentive awards. For analysts, the critical issues include dilution risk, potential anti-takeover effects, and whether the company intends to use the authority for financing transactions; here the company states intent to seek renewal annually. Passage is standard for UK PLCs and expected; failure to approve would constrain the Board’s ability to issue shares promptly and could necessitate additional shareholder meetings for routine financing or equity award fulfilment.

This special resolution asks shareholders to disapply statutory pre-emption rights so the Board can allot shares for cash without first offering them pro rata to existing shareholders, limited to a nominal amount equal to roughly 20% of issued capital and expiring at next AGM or 15 months. Management frames the request as a standard UK corporate governance practice to retain flexibility for timely financings and to avoid the delay and costs of convening a meeting to disapply pre-emption rights in specific instances; it states no present intention to use it except to satisfy incentive awards. The resolution requires a 75% affirmative vote, reflecting its more intrusive potential on shareholder ownership. Analysts should weigh dilution risk against the practical need for financing and equity‑award settlement flexibility; the company discloses the nominal cap and renewal intentions and clarifies the authority’s limited scope. The Board recommends FOR, and institutional investors typically accept modest yearly disapplications if capped and transparently explained; the company’s previous similar authorization and stated intent to renew annually reduce surprise risk. Rejection would limit the Board’s ability to act promptly in capital markets but would protect pre-emption rights of existing shareholders.

This ordinary resolution seeks shareholder approval of the standard form share repurchase contracts (Annex B and C) and of the list of approved counterparties (Annex D) because UK law treats NYSE purchases as “off‑market” repurchases that require pre‑approval of contract forms and counterparties. The resolution specifies a maximum purchase price (110% of last reported sale price), a cap on aggregate repurchases (20% of issued shares as of March 3, 2026), and a limited duration (until next AGM or 15 months). Management recommends FOR and notes the Board earlier authorized a $300 million program (not yet used) and would exercise repurchases at its discretion taking market conditions and liquidity into account. From an investor analysis perspective, this vote is procedural but important: approval permits the company to implement repurchases efficiently subject to the disclosed caps and safeguards; failure to approve would prevent lawful off‑market repurchases and could constrain the company’s capital allocation toolkit. Analysts should monitor actual repurchase activity, funding sources, and potential impact on free float and share overhang.

This proposal requests shareholder approval to amend the Amended and Restated Management Equity Incentive Plan by increasing the authorized share reserve by 2,600,000 ordinary shares (from 31,981,225 to 34,581,225) to ensure an adequate pool for future equity grants to executives and employees. Management argues the increase is needed to sustain the company’s long‑term incentive program, retain talent and maintain alignment with shareholders, and provides governance features intended to limit dilution (no evergreen replenishment, restrictions on liberal recycling, double‑trigger change‑in‑control vesting, and director award caps). The HRCC engaged independent compensation consultants who reviewed plan provisions, dilution impact, historical usage and burn rates and concluded the requested reserve is reasonable for approximately one to two years of expected grants. Analysts should evaluate the incremental dilution (fully‑diluted overhang projected at ~7.1% under certain assumptions) against the company’s talent and retention needs and the strategic pay philosophy; the proxy discloses overhang, share usage history, and the Board’s rationale. If rejected, the company’s ability to grant equity would be materially constrained, potentially affecting competitiveness for key hires and retention, so passage is material to compensation and talent strategy.